Metacel Pharmaceuticals v. Rubicon Research: Baclofen ANDA Dispute Dismissed Without Prejudice
Metacel Pharmaceuticals LLC filed suit against Rubicon Research Private Limited in the District of New Jersey, asserting US10610502B1 covering its Ozobax® baclofen oral solution 5mg/5mL against Rubicon’s ANDA product. The parties jointly sought and obtained a consent dismissal without prejudice in just 71 days, with each side bearing its own costs.
ANDA baclofen dispute exits New Jersey court in 71 days, no merits decided
On 20 February 2025, Metacel Pharmaceuticals LLC filed Civil Action No. 2:25-cv-01382 in the District of New Jersey against Rubicon Research Private Limited. The complaint asserted infringement of US10610502B1, the patent underlying Metacel’s branded Ozobax® baclofen oral solution 5mg/5mL, targeting Rubicon’s corresponding ANDA product. The action is characteristic of Hatch-Waxman paragraph IV litigation, where a brand-name drug patent holder challenges a generic applicant’s FDA filing before any product reaches market.
On 2 May 2025 — just 71 days after filing — the parties submitted a joint application for a Consent Order of Dismissal. The court ordered all claims and counterclaims dismissed without prejudice, with each party bearing its own costs. Dismissal without prejudice means neither party obtained a merits judgment: Metacel retains the right to refile and Rubicon faces no estoppel from the outcome, though no infringement or invalidity findings were made.
The pace of resolution — under three months — is notably swift for ANDA patent litigation, which routinely extends 18–30 months. The consent structure and absence of fee-shifting suggest the parties reached a private accommodation, potentially including a settlement agreement or licensing arrangement whose terms are not disclosed in the public record. The without-prejudice posture leaves Metacel’s patent enforcement position legally intact while Rubicon’s ANDA pathway remains formally unresolved in court.
Filing to Consent Judgment in 71 days
71 days — well below the median ANDA patent litigation duration, suggesting early resolution
Consent dismissal without prejudice: what the order means for both parties
Consent order dismisses all claims — without prejudice
A dismissal without prejudice by consent order means the court terminates the action on joint application of both parties without adjudicating any claim on its merits. No finding of infringement, validity, or enforceability was made. Because the dismissal is without prejudice, Metacel retains the legal right to refile the same claims — subject to applicable statutes of limitations — and Rubicon faces no issue-preclusion or claim-preclusion from this proceeding.
No merits adjudicatedMetacel’s patent remains fully enforceable and un-adjudicated
US10610502B1 emerges from this litigation without any adverse validity or enforceability ruling. Metacel’s without-prejudice dismissal preserves every enforcement option: it may refile against Rubicon if ANDA prosecution or commercial launch resumes, and may assert the patent against other generic filers. The consent structure and self-borne costs suggest Metacel achieved a satisfactory private resolution — possibly a licensing or market-entry agreement — whose terms are not public.
Patent rights intactRubicon avoids adverse judgment but gains no patent clearance
Rubicon Research obtains dismissal of the infringement claims but receives no court ruling that its ANDA product is non-infringing or that Metacel’s patent is invalid. The without-prejudice dismissal means Metacel could re-engage if Rubicon proceeds toward FDA approval or commercial launch without a private agreement in place. Rubicon’s U.S. market entry for baclofen oral solution 5mg/5mL therefore remains contingent on any undisclosed arrangement or future patent clearance.
No patent clearance obtainedPrivate resolution keeps Ozobax® competitive dynamics off the public record
The consent dismissal — reached in 71 days with no disclosed terms — is consistent with a confidential settlement or licensing deal that structures Rubicon’s potential market entry around Metacel’s commercial interests. For other generic filers targeting the baclofen oral solution space, US10610502B1 remains an active and unlitigated obstacle. Brands and generics in the Hatch-Waxman space should note that rapid consent dismissals of this type often signal negotiated entry dates or royalty arrangements.
Confidential resolution likelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Metacel Pharmaceuticals, LLC | Company | Specialty pharmaceutical IP holder — owner of US10610502B1 covering Ozobax® baclofen oral solutionSearch in Eureka ↗ |
| Defendant | Rubicon Research Private Limited | Individual | Indian generic pharmaceutical company seeking U.S. market entry via ANDA for baclofen oral solutionSearch in Eureka ↗ |
| Plaintiff counsel | Christopher S. Casieri | Attorney | Counsel for Metacel Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | WILLIAM HARE | Attorney | Counsel for Metacel Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McNeely, Hare & War LLP | Law Firm | Representing Metacel Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Rubicon Research Private LimitedSearch in Eureka ↗ |
| Defendant law firm | Kratz & Barry, LLP | Law Firm | Representing Rubicon Research Private LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent order is precise in scope: ‘all claims and counterclaims’ are dismissed without prejudice, and costs are explicitly neutralised. The without-prejudice framing is legally significant — it forecloses any res judicata defence by Rubicon in future proceedings and preserves Metacel’s full enforcement posture. The joint application structure signals mutual agreement rather than unilateral withdrawal, suggesting the parties negotiated terms outside the court record. No merits ruling — on infringement, validity, or claim construction — was issued.
US10610502B1 — Baclofen Oral Solution 5mg/5mL Formulation (Ozobax®)
US10610502B1, filed under application number US16/556893, protects a baclofen oral solution formulation — the technology underlying Metacel’s Ozobax® branded drug. Baclofen oral solution is used as a muscle relaxant and antispastic agent, and the liquid 5mg/5mL dosage form is particularly significant for patients unable to swallow tablets. The patent’s granted claims likely cover formulation composition, stability, or manufacturing parameters that distinguish Ozobax® from prior baclofen products.
In the Hatch-Waxman ANDA context, US10610502B1 functions as a market-exclusivity barrier: any generic filer referencing Ozobax® must certify non-infringement or challenge the patent’s validity. The fact that Rubicon’s ANDA product triggered this litigation — and that the case resolved by consent within 71 days — suggests the patent claims are sufficiently broad to pose a credible enforcement threat to oral baclofen generics. Other generic pharmaceutical companies developing baclofen oral liquid formulations should treat this patent as an active competitive obstacle.
Should you run an FTO against US10610502B1 before filing a baclofen ANDA?
Any pharmaceutical company developing, filing, or advancing an ANDA referencing an oral baclofen solution — particularly at the 5mg/5mL concentration — should conduct a freedom-to-operate analysis against US10610502B1 before Paragraph IV certification. The Metacel v. Rubicon case confirms the patent is actively enforced. An FTO gap could expose an ANDA filer to immediate litigation and a potential 30-month FDA approval stay, significantly delaying commercial launch.
PatSnap Eureka’s FTO Search Agent can map US10610502B1 claim scope against your formulation parameters, identify prosecution history estoppel, and surface any continuations or related family members that may extend coverage. Eureka also flags other Metacel portfolio assets relevant to baclofen oral dosage forms, giving R&D and regulatory teams a complete picture before committing to an ANDA filing strategy.
Run a freedom-to-operate analysis on US10610502B1 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases in pharmaceutical oral solutions
Explore comparable Hatch-Waxman patent infringement cases in the District of New Jersey and other U.S. courts involving oral pharmaceutical formulation patents and ANDA disputes.
What this case signals for the ANDA pharmaceutical patent IP landscape
A 71-day Hatch-Waxman dismissal without prejudice is a strong indicator of private deal-making. Here is what it means for pharma IP strategy.
Speed of consent dismissal suggests pre-trial deal — not litigation fatigue
Seventy-one days is too short for substantive ANDA litigation. The joint consent application and mutual cost-bearing are classic markers of a negotiated outcome — possibly a market-entry date agreement or royalty licence. IP teams monitoring Rubicon’s Ozobax® ANDA should watch FDA’s Orange Book for any new patent listings or exclusivity entries.
US10610502B1 remains an undefeated enforcement asset for Metacel
No invalidity, non-infringement, or unenforceability finding was made. The patent exits this litigation with its presumption of validity fully intact. Any competitor filing an ANDA referencing Ozobax® — or launching a baclofen 5mg/5mL oral solution — faces the same enforcement risk that Rubicon faced at filing.
Metacel v Rubicon — key questions answered
The case was dismissed without prejudice by consent order on 2 May 2025, 71 days after filing. All claims and counterclaims were terminated with each party bearing its own costs. No merits ruling on infringement or patent validity was issued.
Metacel asserted US10610502B1, a patent covering its Ozobax® baclofen oral solution 5mg/5mL formulation. The case targeted Rubicon’s corresponding ANDA product seeking FDA approval to market a generic version of Ozobax®.
A dismissal without prejudice preserves Metacel’s right to refile the same patent infringement claims against Rubicon in the future. No preclusion doctrine — res judicata or collateral estoppel — bars a subsequent action. Metacel retains full enforcement rights under US10610502B1.
The court order itself does not resolve Rubicon’s FDA status. The without-prejudice dismissal removes the active litigation but provides no judicial non-infringement or invalidity ruling that would clear Rubicon’s ANDA path. Any impact on FDA’s 30-month stay or approval timeline would depend on terms negotiated privately between the parties.
The case closed in 71 days, far below the 18–30 month median for ANDA patent disputes. The joint consent application and mutual cost-bearing are consistent with a private settlement or licensing arrangement — possibly including a negotiated market-entry date or royalty. The specific terms are not disclosed in the public court record.
PatSnap Eureka searches patents and litigation data to answer instantly.